{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T23:10:51Z","timestamp":1725059451601},"reference-count":16,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0378-6323.152311","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T10:37:32Z","timestamp":1425033452000},"page":"216","source":"Crossref","is-referenced-by-count":7,"title":["Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate"],"prefix":"10.25259","volume":"81","author":[{"given":"Sukhjot","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AmanjotKaur","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JagdevS","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neena","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.152311-1","first-page":"317","volume-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis and management","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.152311-2","first-page":"1471","volume-title":"Imatinib, dasatinib, and nilotinib: A review of adverse cutaneous reactions with emphasis on our clinical experience","author":"Brazzelli","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.152311-3","first-page":"41","volume-title":"Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour","author":"Cheng","year":"2009","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/0378-6323.152311-4","first-page":"270","volume-title":"Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment","author":"Nagai","year":"2013","journal-title":"Eur J Hematol"},{"key":"key-10.4103\/0378-6323.152311-5","first-page":"2542","volume-title":"Nilotinib in imatinib- resistant CML and Philadelphia chromosome- positive ALL","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.152311-6","first-page":"868","volume-title":"Rosacea like eruption associated with nilotinib","author":"Yang","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.152311-7","first-page":"142","volume-title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: Meta-analysis and clinical characterization","author":"Drucker","year":"2013","journal-title":"Eur J Haemtol"},{"key":"key-10.4103\/0378-6323.152311-8","first-page":"1834","volume-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","author":"Le","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.152311-9","unstructured":"Tasigna package insert. Basel, Switzerland: Novartis. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf.[Last accessed on 2014 Feb 8]."},{"key":"key-10.4103\/0378-6323.152311-10","first-page":"406","volume-title":"Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal tumor","author":"Miyagawa","year":"2002","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.152311-11","first-page":"134","volume-title":"Importance of regulatory T cells in the pathogenesis of psoriasis: Review of literature","author":"Mattozzi","year":"2013","journal-title":"Dermatology"},{"key":"key-10.4103\/0378-6323.152311-12","first-page":"6955","volume-title":"Imatinib mesylate inhibits CD4+CD25+regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors","author":"Larmonier","year":"2008","journal-title":"J Immunol"},{"key":"key-10.4103\/0378-6323.152311-13","first-page":"1133","volume-title":"Imatinib impairs the proliferation and function of CD4+CD25+regulatory T cells in a dose dependent manner","author":"Chen","year":"2007","journal-title":"Int J Oncol"},{"key":"key-10.4103\/0378-6323.152311-14","first-page":"2107","volume-title":"Nilotinib hampers the proliferation and function of CD8+T lymphocytes through inhibition of T cell receptor signaling","author":"Chen","year":"2008","journal-title":"J Cell Mol Med"},{"key":"key-10.4103\/0378-6323.152311-15","first-page":"599","volume-title":"Nilotinib inhibits the Src-family kinase LCK and T cell function in vitro","author":"Blake","year":"2009","journal-title":"J Cell Mol Med"},{"key":"key-10.4103\/0378-6323.152311-16","first-page":"22","volume-title":"Effects of nilotinib on regulatory T cells: The dose matters","author":"Fei","year":"2010","journal-title":"Mol Cancer"}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:37:52Z","timestamp":1612658272000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/nilotinib-induced-psoriasis-in-a-patient-of-chronic-myeloid-leukemia-responding-to-methotrexate\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"alternative-id":["152311"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.152311","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}